Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Senate does not negotiate with Baucus

Executive Summary

Medicare direct drug price negotiation bill stalls in the Senate April 18, as Sen. Max Baucus, D-Mont., fails to win enough votes for "cloture," which would bring the Senate to a vote. As passed by the Finance Committee, Baucus' S 3 would permit HHS to negotiate Part D prices with drug manufacturers and add provisions in other areas such as comparative effectiveness research and data sharing with congressional agencies (1"The Pink Sheet" April 16, 2007, p. 4)...

You may also be interested in...

Comparative Effectiveness Bill Calls For Private Group To Plan Research

While getting little exposure in the new Medicare law, comparative effectiveness research is getting full attention in a bill introduced by Sen. Max Baucus, D-Mont., that offers a comprehensive roadmap toward conducting the research and disseminating findings

Medicare Part D Boosts Public Share Of Retail Drug Spending To 34 Percent

The public sector picked up 34 percent of the tab for prescription drugs purchased at retail in 2006, up from 28 percent the year before, with Medicare Part D underlying much of that shift, according to a report by CMS economists

OIG Is Scrutinizing Whether Part D Discounts Are Passed On To Enrollees

The issue of whether Medicare drug plan enrollees see pocketbook savings as a result of Part D drug price concessions is under HHS Office of Inspector General evaluation in a series of ongoing reviews slated for completion in 2008 as well as a newly initiated study

Related Content

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts